KR101765717B1 - 방사성 식별을 위한 디티피에이 덱스트란 조성물 - Google Patents

방사성 식별을 위한 디티피에이 덱스트란 조성물 Download PDF

Info

Publication number
KR101765717B1
KR101765717B1 KR1020177005797A KR20177005797A KR101765717B1 KR 101765717 B1 KR101765717 B1 KR 101765717B1 KR 1020177005797 A KR1020177005797 A KR 1020177005797A KR 20177005797 A KR20177005797 A KR 20177005797A KR 101765717 B1 KR101765717 B1 KR 101765717B1
Authority
KR
South Korea
Prior art keywords
dtpa
dextran
sodium
mannosyl
composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related
Application number
KR1020177005797A
Other languages
English (en)
Korean (ko)
Other versions
KR20170027874A (ko
Inventor
제랄드 로스 마그네슨
리차드 쿠쉬만 오라후드
Original Assignee
나비디아 바이오파마슈티컬즈, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 나비디아 바이오파마슈티컬즈, 인크. filed Critical 나비디아 바이오파마슈티컬즈, 인크.
Publication of KR20170027874A publication Critical patent/KR20170027874A/ko
Application granted granted Critical
Publication of KR101765717B1 publication Critical patent/KR101765717B1/ko
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/005—Sugars; Derivatives thereof; Nucleosides; Nucleotides; Nucleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/0491—Sugars, nucleosides, nucleotides, oligonucleotides, nucleic acids, e.g. DNA, RNA, nucleic acid aptamers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02—Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04—Organic compounds
    • A61K51/06—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules
    • A61K51/065—Macromolecular compounds, carriers being organic macromolecular compounds, i.e. organic oligomeric, polymeric, dendrimeric molecules conjugates with carriers being macromolecules
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/004—Acyclic, carbocyclic or heterocyclic compounds containing elements other than carbon, hydrogen, halogen, oxygen, nitrogen, sulfur, selenium or tellurium
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B63/00—Purification; Separation; Stabilisation; Use of additives
    • C07B63/04—Use of additives
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/531—Production of immunochemical test materials
    • G01N33/532—Production of labelled immunochemicals
    • G01N33/534—Production of labelled immunochemicals with radioactive label
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/58—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances
    • G01N33/60—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving labelled substances involving radioactive labelled substances
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Optics & Photonics (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Polysaccharides And Polysaccharide Derivatives (AREA)
KR1020177005797A 2009-01-30 2010-01-28 방사성 식별을 위한 디티피에이 덱스트란 조성물 Expired - Fee Related KR101765717B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US12/362,778 US20100196272A1 (en) 2009-01-30 2009-01-30 Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
US12/362,778 2009-01-30
PCT/US2010/000222 WO2010087959A1 (en) 2009-01-30 2010-01-28 Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
KR1020117020202A Division KR101713559B1 (ko) 2009-01-30 2010-01-28 방사성 식별을 위한 디티피에이 덱스트란 조성물

Publications (2)

Publication Number Publication Date
KR20170027874A KR20170027874A (ko) 2017-03-10
KR101765717B1 true KR101765717B1 (ko) 2017-08-07

Family

ID=42395938

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177005797A Expired - Fee Related KR101765717B1 (ko) 2009-01-30 2010-01-28 방사성 식별을 위한 디티피에이 덱스트란 조성물
KR1020117020202A Expired - Fee Related KR101713559B1 (ko) 2009-01-30 2010-01-28 방사성 식별을 위한 디티피에이 덱스트란 조성물

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020117020202A Expired - Fee Related KR101713559B1 (ko) 2009-01-30 2010-01-28 방사성 식별을 위한 디티피에이 덱스트란 조성물

Country Status (9)

Country Link
US (4) US20100196272A1 (cg-RX-API-DMAC7.html)
EP (2) EP2392012B1 (cg-RX-API-DMAC7.html)
JP (5) JP5743905B2 (cg-RX-API-DMAC7.html)
KR (2) KR101765717B1 (cg-RX-API-DMAC7.html)
CN (1) CN102301429A (cg-RX-API-DMAC7.html)
AU (1) AU2010208624B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI1007487A2 (cg-RX-API-DMAC7.html)
CA (1) CA2750230C (cg-RX-API-DMAC7.html)
WO (1) WO2010087959A1 (cg-RX-API-DMAC7.html)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
JP6163698B2 (ja) * 2013-03-21 2017-07-19 国立大学法人 千葉大学 マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物
US20150023876A1 (en) 2013-07-22 2015-01-22 Navidea Biopharmaceuticals, Inc. Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
JP5924795B2 (ja) 2014-06-13 2016-05-25 テンボロン オイ 複合体
US10806803B2 (en) 2014-07-17 2020-10-20 Ohio State Innovation Foundation Compositions for targeting macrophages and other CD206 high expressing cells and methods of treating and diagnosis
WO2016011415A2 (en) * 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same
EP3218352B1 (en) * 2014-11-13 2020-08-05 Waters Technologies Corporation Method for liquid chromatography calibration for labeled n-glycans, method for preparing a dextran ladder calibrant and calibrant
GB201504064D0 (en) 2015-03-10 2015-04-22 Accretion Biotechnology Ltd Method and kits for preparing radionuclide complexes
CN106317237B (zh) * 2015-07-03 2019-07-19 华中科技大学 一种用于spect成像的当归多糖衍生物及其合成方法
CN106188226B (zh) * 2016-07-04 2019-12-24 江苏省原子医学研究所 一种用于淋巴结检查的大分子显像剂及其制备方法
FR3054445B1 (fr) * 2016-07-26 2019-07-05 Laboratoires Cyclopharma Synthese d'une composition d'agent radioactif
US10695450B2 (en) 2016-07-26 2020-06-30 Laboratoires Cyclopharma Synthesis of a radioactive agent composition
US11007272B1 (en) 2016-10-07 2021-05-18 Navidea Biopharmaceuticals, Inc. Compounds and methods for diagnosis and treatment of viral infections
JP6329302B2 (ja) * 2017-05-10 2018-05-23 国立大学法人千葉大学 マクロファージマンノース受容体を認識する新規多糖金属錯体化合物、及び、その医薬組成物
WO2020202831A1 (ja) * 2019-03-29 2020-10-08 国立研究開発法人量子科学技術研究開発機構 放射性医薬の製造方法及び放射性医薬
JP2023533405A (ja) 2020-07-08 2023-08-03 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド 均一に定められた分子量のマンノシル化デキストランおよびその誘導体の合成
US12006339B2 (en) 2022-05-20 2024-06-11 Navidea Biopharmaceuticals, Inc. CD206 targeted drug delivery vehicles carrying novel bisphosphonate drug payloads via a degradable linker
JP2025535006A (ja) 2022-10-03 2025-10-22 ナビディア、バイオファーマスーティカルズ、インコーポレイテッド 炭水化物ポリマーに結合されたアミン終端リーシュへの糖部分のアミド結合

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IT1053508B (it) * 1970-07-06 1981-10-10 Searle & Co Procedimento per prepare composizioni marcate adatte a mettere in evidenza alterazioni della mucosa gastrointestinale prodotto ottenuto e relativo metodo di impiego
US4364920A (en) * 1975-04-30 1982-12-21 Medi-Physics, Inc. Stable diagnostic reagents
US4048296A (en) * 1975-05-27 1977-09-13 Mallinckrodt, Inc. Radiopharmaceutical scanning agents
JPS5569517A (en) * 1978-11-20 1980-05-26 Nippon Mejifuijitsukusu Kk Labelling preparation for labelling of erythrocytes with radio-active technetium
SE465907B (sv) 1984-11-01 1991-11-18 Nyegaard & Co As Diagnosticeringsmedel innehaallande en paramagnetisk metall
US5336762A (en) 1985-11-18 1994-08-09 Access Pharmaceuticals, Inc. Polychelating agents for image and spectral enhancement (and spectral shift)
US4822594A (en) 1987-01-27 1989-04-18 Gibby Wendell A Contrast enhancing agents for magnetic resonance images
CS263561B1 (en) 1987-09-18 1989-04-14 Kery Vladimir Process for preparing water soluble allylderivatives of oligo and polysaccharides
GB8801646D0 (en) * 1988-01-26 1988-02-24 Nycomed As Chemical compounds
US5328679A (en) * 1988-04-01 1994-07-12 Immunomedics, Inc. Methods for technetium/rhenium labeling of proteins
DD286598A5 (de) 1989-06-29 1991-01-31 Adw Der Ddr,Zi F. Mulekularbiologie,De Verfahren zur einfuehrung von primaeren aminogruppen in wasserloesliche polymere
EP0516873A1 (en) * 1991-06-06 1992-12-09 THE STATE of ISRAEL Atomic Energy Commission Soreq Nuclear Research Center A method and kit for protein labelling with 99 mTC
US5789578A (en) 1996-01-11 1998-08-04 Massey University Methods for the preparation of resins with ligands attached thereto through a linking group comprising sulfide, sulfoxide or sulfone functionality
US20010055563A1 (en) * 1999-09-09 2001-12-27 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
US6066309A (en) * 1996-02-02 2000-05-23 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
WO1997028181A2 (en) * 1996-02-02 1997-08-07 Rhomed Incorporated Post-labeling stabilization of radiolabeled proteins and peptides
AU5135698A (en) 1996-11-28 1998-06-22 Nihon Schering K.K. Contrast compound, contrast medium for mri, and method for mri
ES2228536T3 (es) 1999-05-14 2005-04-16 The Regents Of The University Of California Soporte macromolecular a base de dextrano para un farmaco y suministro de un agente de diagnosotico.
US6887462B2 (en) * 2001-04-09 2005-05-03 Chiron Corporation HSA-free formulations of interferon-beta
US7666979B2 (en) 2002-03-01 2010-02-23 Bracco International B.V. Methods for preparing multivalent constructs for therapeutic and diagnostic applications and methods of preparing the same
MXPA04011624A (es) * 2002-05-24 2005-03-07 Schering Corp Anticuerpo neutralizante humano anti-igfr.
CA2517939C (en) 2003-03-03 2015-11-24 Dyax Corp. Peptides that specifically bind hgf receptor (cmet) and uses thereof
DE602005001833T2 (de) * 2004-10-29 2008-04-17 Pharma Mar S.A., Sociedad Unipersonal Zusammensetzungen enthaltend Ecteinascidin und einen Disaccharide
TWI398272B (zh) * 2005-03-08 2013-06-11 Intervet Int Bv 化學定義的安定劑
US20090155351A1 (en) * 2005-10-04 2009-06-18 Alk-Abello A/S Solid Vaccine Formulation
AU2007234612B2 (en) * 2006-12-14 2013-06-27 Johnson & Johnson Regenerative Therapeutics, Llc Protein stabilization formulations
EA019345B1 (ru) * 2007-03-05 2014-03-31 Кадила Хелзкэр Лимитед Композиции, содержащие конъюгаты пэг-интерферон-альфа и рафинозу в качестве криопротектора
US20100196272A1 (en) 2009-01-30 2010-08-05 Neoprobe Corporation Compositions for radiolabeling diethylenetriaminepentaacetic acid (dtpa)-dextran
US20150023876A1 (en) 2013-07-22 2015-01-22 Navidea Biopharmaceuticals, Inc. Compositions, methods and kits for diagnosing and treating cd206 expressing cell-related disorders
EP3169336A4 (en) 2014-07-17 2018-04-04 Ohio State Innovation Foundation Compositions for targeting macrophages and other cd206 high expressing cells and methods of treating and diagnosis
WO2016011415A2 (en) 2014-07-17 2016-01-21 Ohio State Innovation Foundation Compounds and compositions for targeting macrophages and other mannose-binding c-type lectin receptor high expressing cells and methods of treating and diagnosis using same

Also Published As

Publication number Publication date
JP2021088566A (ja) 2021-06-10
JP2012516328A (ja) 2012-07-19
US20160347679A1 (en) 2016-12-01
CA2750230C (en) 2018-06-05
AU2010208624B2 (en) 2016-02-04
CA2750230A1 (en) 2010-08-05
CN102301429A (zh) 2011-12-28
KR101713559B1 (ko) 2017-03-08
EP2392012A4 (en) 2012-11-14
JP2019178133A (ja) 2019-10-17
US20100196272A1 (en) 2010-08-05
US20140023586A1 (en) 2014-01-23
WO2010087959A1 (en) 2010-08-05
US8545808B2 (en) 2013-10-01
AU2010208624A1 (en) 2011-08-25
EP2392012B1 (en) 2021-01-20
JP6833892B2 (ja) 2021-02-24
KR20110115148A (ko) 2011-10-20
JP2017066148A (ja) 2017-04-06
EP2392012A1 (en) 2011-12-07
US9439985B2 (en) 2016-09-13
JP6509796B2 (ja) 2019-05-08
JP2015164933A (ja) 2015-09-17
US20120213700A1 (en) 2012-08-23
KR20170027874A (ko) 2017-03-10
EP3884965A1 (en) 2021-09-29
BRPI1007487A2 (pt) 2018-02-20
JP6040276B2 (ja) 2016-12-07
JP5743905B2 (ja) 2015-07-01

Similar Documents

Publication Publication Date Title
KR101765717B1 (ko) 방사성 식별을 위한 디티피에이 덱스트란 조성물
BR112018076593B1 (pt) Composto para radiomarcação, composto radiofarmacêutica, e composição radiofarmacêutica
Callahan et al. Preclinical evaluation and phase I clinical trial of a 99mTc-labeled synthetic polymer used in blood pool imaging.
Meléndez-Alafort et al. Detection of sites of infection in mice using 99mTc-labeled PN2S-PEG conjugated to UBI and 99mTc-UBI: a comparative biodistribution study
Kahts et al. Recently developed radiopharmaceuticals for bacterial infection imaging
EP1437145A1 (en) Enhanced scintigraphic imaging agents for imaging of infection and inflammation
EP0788377B1 (en) Radiolabelled glucans
IL279478B1 (en) A preparation containing a somatostatin analog for radiopharmaceutical use
WO2015063746A1 (en) Pharmaceutical composition
CA3112060A1 (en) Pharmaceutical composition comprising a radiolabeled gprp antagonist and a surfactant
EP4442285A1 (en) Stabilized radiopharmaceutical composition
US20250127941A1 (en) Detection and localization of internal bleeding
JP2001507345A (ja) 多糖ペプチド誘導体
Nunez et al. Parameters optimization defined by statistical analysis for cysteine–dextran radiolabeling with technetium tricarbonyl core
WO2003104267A1 (en) Kit formulation of a novel peptide c-aca-qalgnqwavghlmnh2
Yan et al. Pharmacokinetics of gene recombined angiogenesis inhibitor Kringle 5 in vivo using 131I specific markers and SPECT/CT
WO1997026922A1 (en) 99mTc-TERTIARY-BUTYL ISONITRILE AND ANALOGS AS BREAST TUMOR IMAGING AGENTS

Legal Events

Date Code Title Description
A107 Divisional application of patent
PA0104 Divisional application for international application

St.27 status event code: A-0-1-A10-A18-div-PA0104

St.27 status event code: A-0-1-A10-A16-div-PA0104

PG1501 Laying open of application

St.27 status event code: A-1-1-Q10-Q12-nap-PG1501

PA0201 Request for examination

St.27 status event code: A-1-2-D10-D11-exm-PA0201

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

St.27 status event code: A-1-2-D10-D22-exm-PE0701

GRNT Written decision to grant
PR0701 Registration of establishment

St.27 status event code: A-2-4-F10-F11-exm-PR0701

PR1002 Payment of registration fee

St.27 status event code: A-2-2-U10-U12-oth-PR1002

Fee payment year number: 1

PG1601 Publication of registration

St.27 status event code: A-4-4-Q10-Q13-nap-PG1601

R18-X000 Changes to party contact information recorded

St.27 status event code: A-5-5-R10-R18-oth-X000

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 4

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 5

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 6

PR1001 Payment of annual fee

St.27 status event code: A-4-4-U10-U11-oth-PR1001

Fee payment year number: 7

PC1903 Unpaid annual fee

St.27 status event code: A-4-4-U10-U13-oth-PC1903

Not in force date: 20240802

Payment event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

PC1903 Unpaid annual fee

St.27 status event code: N-4-6-H10-H13-oth-PC1903

Ip right cessation event data comment text: Termination Category : DEFAULT_OF_REGISTRATION_FEE

Not in force date: 20240802